Method of Producing Immortalized Primary Human Keratinocytes for HPV Investigation, Testing of Therapeutics, and Skin Graft Generation

Description:
One of the major limitations of using cultured keratinocytes for research studies is that primary keratinocytes senesce after a few passages. Keratinocytes from specific anatomical sites are also difficult to culture. Scientists at the NIH have demonstrated that primary keratinocytes, from several anatomical sites, when treated with a small-molecule inhibitor of the ROCK protein maintain a proliferative state and become immortal without genetic modification to the cells. Keratinocytes are also the host cells for human papillomaviruses (HPVs) and other viruses and this technology enables the study of those viruses that do not immortalize cells. In addition, this technology may enhance the quantity of material available for skin grafts, as current grafting techniques are limited by the amount of donor material immediately available. Thus, this technology may provide an ideal model environment for producing large quantities of both normal and diseased primary human keratinocytes from small numbers of primary cells from individual hosts or anatomical sites for research purposes, testing of therapeutics, skin graft generation and HPV investigation.
Patent Information:
For Information, Contact:
Benjamin Hurley
Office of Technology Transfer Center
NIH Technology Transfer
240-669-5092
benjamin.hurley@nih.gov
Inventors:
Sandra Chapman
Jonathan Vogel
Atsushi Terunuma
Alison McBride
Keywords:
AC4XXX
ACXXXX
AXXXXX
CC3XXX
CCXXXX
Complete
CXXXXX
DDXXXX
DXXXXX
EXTENDED
grafting
Human
IB2BXX
IB2XXX
IBXXXX
inhibitor
IXXXXX
KERATINOCYTES
Keratinocytes.
Life-cycle
LONG-TERM
Maintenance
Papillomaviruses.
Patent Category - Biotechnology
Persistence
Primary
PROLIFERATIVE
REPLICATION
ROCK
RXXXXX
SKIN
STATE
Studies.
Sustain
Y-27632
© 2024. All Rights Reserved. Powered by Inteum